A Retrospective Analysis Of Treatment Of Advanced Breast Cancer In 10 Years

Objective:The purpose of this study is to retrospectively analyze the clinical pathologic characteristics,Metastatic sites treatment and their correlation to prognosis of 777 breast cancer patients who had been treated in our tumor center.Methods:From January 2007 to December 2016 at the cancer center in our hospital for treatment of 777 cases of advanced breast cancer with the basic information,clinical and pathological features,treatment and follow-up and prognosis,improve the database of advanced breast cancer were retrospectively analyzed,using data analysis software,understand the advanced breast cancer recurrence and metastasis,clinical treatment well,the risk factors influencing the prognosis.Results:1.The 1st line of chemotherapy in advanced breast cancer based on paclitaxel,besides the 2nd and 3rd line used paclitaxel and platinum most.2.The plan of the first-line chemotherapy in advanced breast cancer was paclitaxel + anthracycline,and the 2nd and 3rd line treatment is a variety of treatment programs coexist.3.The pathology of advanced breast cancer is different from the initial treatment in Ki-67,ER/PR,HER-2 and molecular type.And the trend of recurrence is more invasive and worse prognosis.4.The location of the first recurrence of breast cancer is related to the molecular classification and the stage of the disease.The over expression of Her-2 is trend to distant metastasis.The disease stage is higher and it is trend to distant metastasis.The number of metastatic organs is related to the risk of disease recurrence.The higher the risk of recurrence,the more the number of metastatic organs.5.The results of advanced breast cancer of single factor analysis show that the pathological type,TNM stage,ER/PR,risk stratification,histological grade,metastasis and metastasis number significantly affected the OS(P<0.05).Multivariate analysis showed that the number of metastatic sites and ER/PR were independent prognostic factors in patients with breast cancer,ER/PR++ and metastasis number less than 3 of the patients with good prognosis.Conclusion:1.The survival rates of 1,3 and 5 years in advanced breast cancer were 90%,69% and 55%,respectively.The median survival time was 78 months,and the number of ER/PR and metastasis organs was the independent risk factor for the prognosis of advanced breast cancer.2.Anatomical staging can not fully reflect the prognosis of patients,and the functional staging which means the anatomical stages combine the biological characteristics of tumor cells is the index to evaluate the prognosis of breast cancer in the future.3.The pathological parameters may change after the recurrence of advanced breast cancer,and to a higher degree of malignancy,more aggressive direction,so the second biopsy is important and guiding for the treatment and prognosis analysis.